James H. Thrall Sells 1,000 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

by · The Markets Daily

Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Lantheus Stock Down 0.1 %

Shares of LNTH traded down $0.11 during trading hours on Friday, reaching $91.47. The company’s stock had a trading volume of 585,479 shares, compared to its average volume of 746,461. The company has a 50 day moving average of $89.64 and a two-hundred day moving average of $99.77. The firm has a market cap of $6.36 billion, a price-to-earnings ratio of 15.22 and a beta of 0.46. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of LNTH. Envestnet Asset Management Inc. lifted its position in shares of Lantheus by 0.3% in the second quarter. Envestnet Asset Management Inc. now owns 111,498 shares of the medical equipment provider’s stock worth $8,952,000 after buying an additional 356 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Lantheus by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after acquiring an additional 19,071 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Lantheus by 142.8% in the 2nd quarter. Renaissance Technologies LLC now owns 215,431 shares of the medical equipment provider’s stock worth $17,297,000 after purchasing an additional 126,700 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Lantheus during the second quarter worth approximately $209,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in Lantheus by 20.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,025 shares of the medical equipment provider’s stock valued at $564,000 after purchasing an additional 1,202 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LNTH. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Truist Financial reissued a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Check Out Our Latest Analysis on LNTH

About Lantheus

(Get Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

See Also